alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit 32.1**     DAC TECHNOLOGIES GROUP INTERNATIONAL, INC. CERTIFICATION PURSUANT TO 18 U.S.C. SECTION1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002     In connection with the Annual Report on Form 10-KSB of DAC Technologies Group InternationalInc (the “Company”) for the period ended December 31, 2007 as filed with the Securities andExchange Commission on the date hereof (the “Report”), Robert C. Goodwin, Chief FinancialOfficer of the Company, hereby certifies, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant toss. 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with therequirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) Theinformation contained in the Report fairly presents, in all material respects, the financialcondition and results of operations of the Company.                 /s/ Robert C. Goodwin   Robert C. Goodwin, CFO, Principal Accounting Officer and Principal Financial Officer      Date:March 31, 2008
#### The People of the State of New York, Respondent, v Roberto Ovalle, Appellant.

Judgments of the Supreme Court, New York County (Juanita Bing Newton, J.), both rendered October 6, 1988, convicting defendant, after a jury trial, of criminal sale of a controlled substance in the third degree and, upon his plea of guilty, of criminal sale of a controlled substance in the fifth degree, and sentencing him, as a predicate felon, to concurrent indeterminate prison terms of from 4 Vi to 9 years and from 2 to 4 years on the third and fifth degree sale convictions, respectively, are unanimously affirmed.

Defendant’s conviction arose from his sale of narcotics to undercover officers on two separate occasions. Defendant was first tried and convicted on the second sale. Subsequently, *157defendant pleaded guilty to cover the indictment arising from the first sale and, on the same day, he was sentenced for both convictions.

On appeal, defendant argues that the prosecutor, at trial, impermissibly shifted the burden of proof in his summation by asserting that there was "no proof’ in the record to support some of the defense arguments.

The theory of the defense was that of mistaken identification. In support of this theory, defense counsel, on summation, attacked the credibility of the undercover officers who testified, and he also hypothesized that the actual seller might have evaded the police by exiting the back door of the apartment building where the drugs were sold. Notably, there was no evidence adduced at trial to support this theory. As such, the challenged remarks made by the prosecutor on summation were a fair response to the defense summation *(see, People v Marks,*6 NY2d 67, 77-78, *cert denied*362 US 912). Indeed, a prosecutor is permitted to comment on the lack of evidence or testimony supporting a defendant’s claim *(People v Ashwal,*39 NY2d 105, 109-110). We also note that the prosecutor’s comments were subsequently clarified by the court in its curative instructions *(see, People v Galloway,*54 NY2d 396, 399).

Vacatur of defendant’s subsequent plea of guilty under the first indictment (arising from the first sale) is inappropriate where defendant has failed to make a showing that the plea was predicated upon an improperly obtained conviction *(see, e.g., People v Rogers,*48 NY2d 167, 174-175). Concur—Kupferman, J. P., Sullivan, Asch, Wallach and Smith, JJ.
EXHIBIT 32.2



CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



I, Dan Moses, Chief Financial Officer of SimpleTech, Inc. (the Company), certify, pursuant to 18 U.S.C. § 1350, as adopted
pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:



| | (1) | the Annual Report of the Company on Form 10-K for the fiscal year ended December 31, 2004, as filed with the Securities and Exchange Commission (the Report), fully
complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                                                
|------------------------------------------------
|/s/ DAN MOSES                                   
|Dan Moses Chief Financial Officer March 11, 2005
AMENDMENT TO OSI PARTNER EQUITY PLAN


     

    Exhibit
      10.7


    AMENDMENT
      TO OUTBACK STEAKHOUSE, INC.

     

    PARTNER
      EQUITY PLAN

     

    


     

    WHEREAS,
      in connection with the transactions contemplated by the Agreement and Plan
      of
      Merger among Kangaroo Holdings, Inc., Kangaroo Acquisition, Inc. and Outback
      Steakhouse, Inc. (the “Company”), dated as of November 5, 2006 (the “Merger
      Agreement”), the Board of Directors (the “Board”) and the Compensation Committee
      of the Board of Directors (the “Committee”) have determined as required by the
      Merger Agreement to amend and construe the Outback Steakhouse, Inc. Partner
      Equity Plan (the “Plan”) as permitted by Section 7 of the Plan. 

     

    NOW
      THEREFORE, the Plan is hereby amended effective immediately with respect to
      all
      accounts thereunder, as follows:

     

    The
      following Section 3.7 is hereby added after Section 3.6 of the Plan:


    


    3.7 Effect
      of the Merger.
      Notwithstanding anything to the contrary in the Plan or otherwise, effective
      as
      of the “Effective Time” (as defined in the Agreement
      and Plan of Merger among Kangaroo Holdings, Inc., Kangaroo Acquisition, Inc.
      and
      the Corporation, dated as of November 5, 2006 (the “Merger Agreement”), the
      phantom shares of Company Stock credited to each Participant’s Account will
be
      converted into an obligation to pay cash with a value equal to the product
      of
      (A) the “Merger Consideration” (as defined in the Merger Agreement) and (B) the
      number of shares of Company Stock credited in such Account (the “Converted
      Account”). From and after the Effective Time, the amounts credited to a
      Participant’s Converted Account will be eligible to be invested by such
      Participant in the investment alternatives available under the Partner Equity
      Deferred Compensation Diversified Plan and, except for such administrative
      changes as may be necessary to effectuate the foregoing, the Converted Account
      will be administered in accordance with the payment schedule and consistent
      with
      the terms of the Plan.

    


    Except
      as
      expressly modified hereby, the terms and provisions of the Plan shall remain
      in
      full force and effect. In the event the Merger Agreement is terminated in
      accordance with its terms, this Amendment shall be void ab
      initio
      and of
      no force and effect.
<TABLE> <S> <C>

<ARTICLE> 9
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S FINANCIAL STATEMENTS FOR THE YEAR ENDED SEPTEMBER 30, 2000 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          SEP-30-2000
<PERIOD-START>                             OCT-01-1999
<PERIOD-END>                               SEP-30-2000
<CASH>                                          33,777
<INT-BEARING-DEPOSITS>                             970
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                    991,766
<INVESTMENTS-CARRYING>                          27,598
<INVESTMENTS-MARKET>                            27,001
<LOANS>                                      1,305,368
<ALLOWANCE>                                     10,404
<TOTAL-ASSETS>                               2,493,083
<DEPOSITS>                                   1,471,881
<SHORT-TERM>                                   758,581
<LIABILITIES-OTHER>                             25,603
<LONG-TERM>                                    106,095
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           146
<OTHER-SE>                                     130,777
<TOTAL-LIABILITIES-AND-EQUITY>               2,493,083
<INTEREST-LOAN>                                100,922
<INTEREST-INVEST>                               71,315
<INTEREST-OTHER>                                 2,417
<INTEREST-TOTAL>                               174,654
<INTEREST-DEPOSIT>                              72,465
<INTEREST-EXPENSE>                             120,731
<INTEREST-INCOME-NET>                           53,923
<LOAN-LOSSES>                                    2,509
<SECURITIES-GAINS>                                  12
<EXPENSE-OTHER>                                  9,504
<INCOME-PRETAX>                                 16,487
<INCOME-PRE-EXTRAORDINARY>                      16,487
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    11,123
<EPS-BASIC>                                       1.13
<EPS-DILUTED>                                     1.12
<YIELD-ACTUAL>                                    2.24
<LOANS-NON>                                     12,977
<LOANS-PAST>                                       302
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                 9,356
<CHARGE-OFFS>                                    1,563
<RECOVERIES>                                       102
<ALLOWANCE-CLOSE>                               10,404
<ALLOWANCE-DOMESTIC>                            10,404
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0


</TABLE>
IN THE SUPREME COURT OF PENNSYLVANIA

In the Matter of

MONICA VIRMANI SABNIS

PETITION FOR REINSTATEMENT

FROM INACTIVE STATUS

:

:

:

:

:

:

:

No. 77 DB 2018 (No. 43 RST 2018)

Attorney Registration No. 204251

(Out of State)

O R D E R

PER CURIAM

AND NOW, this 1

st day of August, 2018, the Report and Recommendation of 

Disciplinary Board Member dated July 23, 2018, is approved and it is ORDERED that

Monica Virmani Sabnis, who has been on Inactive Status, has never been suspended or 

disbarred, and has demonstrated that she has the moral qualifications, competency and 

learning in law required for admission to practice in the Commonwealth, shall be and is, 

hereby reinstated to active status as a member of the Bar of this Commonwealth. The 

expenses incurred by the Board in the investigation and processing of this matter shall 

be paid by the Petitioner.
Exhibit 32.1

CERTIFICATION

In connection with the Quarterly Report on Form 10-Q of Accentia Biopharmaceuticals, Inc. (the
Company) for the three months ended December 31, 2007, as filed with the Securities and Exchange Commission on the date hereof (the Form 10-Q), I, Francis E. ODonnell, Jr., Chairman of the Board and Chief Executive
Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended: and

(2)
The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 14, 2008



|                                                        
|--------------------------------------------------------
|/s/ Francis E. ODonnell, Jr.                           
|Francis E. ODonnell, Jr., M.D.                         
|Chief Executive Officer; Chairman of the Board; Director

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and
Exchange Commission, and is not to be incorporated by reference into any filing of Accentia Biopharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the
date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [Docket No. DEA-847]
 AGENCY: Drug Enforcement Administration, Justice.
 ACTION: Notice of application.
 SUMMARY: Cambrex Charles City has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.
 DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before July 12, 2021. Such persons may also file a written request for a hearing on the application on or before July 12, 2021.
 ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.


SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 6, 2021, Cambrex Charles City, 1205 11th Street, Charles City, Iowa 50616-3466, applied to be registered as an importer of the following basic class(es) of controlled substance(s): Controlled substance
Drug code
Schedule4-Anilino-N-Phenethyl-4-Piperidine (ANPP)
8333
IIPhenylacetone
8501
IICoca leaves
9040
IIOpium, raw
9600
IIPoppy Straw Concentrate
9670
II
 The company plans to import the listed controlled substances for internal use and to bulk manufacture other controlled substances in Active Pharmaceutical Ingredient (API) form for distribution to its customers. No other activity for these drug codes is authorized for this registration. William T. McDermott, Assistant Administrator.


[FR Doc. 2021-12215 Filed 6-9-21; 8:45 am] BILLING CODE 4410-09-P
<TABLE> <S> <C>

<ARTICLE> 9

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                      13,052,113
<INT-BEARING-DEPOSITS>                         869,009
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                103,253,784
<INVESTMENTS-CARRYING>                               0
<INVESTMENTS-MARKET>                                 0
<LOANS>                                    267,245,600
<ALLOWANCE>                                  3,088,257
<TOTAL-ASSETS>                             392,285,472
<DEPOSITS>                                 289,439,659
<SHORT-TERM>                                19,350,000
<LIABILITIES-OTHER>                          6,146,550
<LONG-TERM>                                 47,000,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     2,873,405
<OTHER-SE>                                  27,475,857
<TOTAL-LIABILITIES-AND-EQUITY>             392,285,472
<INTEREST-LOAN>                             19,975,531
<INTEREST-INVEST>                            6,471,603
<INTEREST-OTHER>                                72,001
<INTEREST-TOTAL>                            26,519,135
<INTEREST-DEPOSIT>                           8,816,154
<INTEREST-EXPENSE>                          11,305,951
<INTEREST-INCOME-NET>                       15,213,184
<LOAN-LOSSES>                                  840,000
<SECURITIES-GAINS>                             265,822
<EXPENSE-OTHER>                              9,295,826
<INCOME-PRETAX>                              6,875,870
<INCOME-PRE-EXTRAORDINARY>                   4,564,548
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 4,564,548
<EPS-BASIC>                                       1.62
<EPS-DILUTED>                                     1.60
<YIELD-ACTUAL>                                    4.37
<LOANS-NON>                                    777,961
<LOANS-PAST>                                   599,955
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                           (2,756,502)
<CHARGE-OFFS>                                  554,095
<RECOVERIES>                                    45,850
<ALLOWANCE-CLOSE>                          (3,088,257)
<ALLOWANCE-DOMESTIC>                       (2,627,472)
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                      (460,785)


</TABLE>
Exhibit 32.2



Certification of the Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350,

As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002



In
connection with the Quarterly Report of WMG Acquisition Corp. (the Company) on Form 10-Q for the period ended December 31, 2005 as filed with the Securities and Exchange Commission on the date hereof (the Report), I,
Michael D. Fleisher, Chief Financial Officer of WMG Acquisition Corp., certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



|(1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|--- | ---------------------------------------------------------------------------------------------------------------------



|(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------



Dated: February 14, 2006



/S/    MICHAEL D.
FLEISHERMichael D. Fleisher Chief Financial Officer
EXHIBIT 31.1
 SECTION 302 CERTIFICATION
      (a)
    
    Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known to
us by others within those entities, particularly during the period in
which this report is being prepared;(b)
    
    Designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted
accounting principles;(c)
    
    Evaluated the effectiveness of the registrants disclosure controls
and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and(d)
    
    Disclosed in this report any change in the registrants internal
control over financial reporting that occurred during the registrants
most recent fiscal quarter (the registrants fourth fiscal quarter in
the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrants internal
control over financial reporting.
  (a)
    
    All significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrants ability to
record, process, summarize and report financial information; and(b)
    
    Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrants internal
control over financial reporting.
  /s/ Richard J. LampenRichard J. LampenChief Executive Officer
(Principal Executive Officer) 31
CERTIFICATION PURSUANT TO
         18 U.S.C. SECTION 1350
          AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cross Atlantic Commodities,
Inc. (the "Company") on Form 10-QSB for the six months ended June 30,
2007 as filed with the Securities and Exchange Commission on the date
hereof (the "Report"), I, Michael Enemaerke, Chief Executive Officer of
the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
            (1) The Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
           (2) The information contained in the Report fairly presents,
in all material respects, the financial condition and result of
operations of the Company.

/s/Michael Enemaerke
-----------------------------
Michael Enemaerke
Chief Executive Officer

August 20, 2007


        CERTIFICATION PURSUANT TO
         18 U.S.C. SECTION 1350
          AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cross Atlantic Commodities,
Inc. (the "Company") on Form 10-QSB for the six months ended June 30,
2007 as filed with the Securities and Exchange Commission on the date
hereof (the "Report"), I, Kim Beck-Nielsen, Chief Financial Officer of
the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
            (1) The Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
           (2) The information contained in the Report fairly presents,
in all material respects, the financial condition and result of
operations of the Company.

/s/ Kim Beck Nielsen
-----------------------------
Kim Beck Nielsen
Chief Financial Officer

August 20, 2007